Elongator protein 3 (ELP3) acetylates histones in the nucleus but also plays a role in the cytoplasm. Here, we report that in Drosophila neurons, ELP3 is necessary and sufficient to acetylate the ELKS family member Bruchpilot, an integral component of the presynaptic density where neurotransmitters are released. We find that in elp3 mutants, presynaptic densities assemble normally, but they show morphological defects such that their cytoplasmic extensions cover a larger area, resulting in increased vesicle tethering as well as a more proficient neurotransmitter release. We propose a model where ELP3-dependent acetylation of Bruchpilot at synapses regulates the structure of individual presynaptic densities and neurotransmitter release efficiency.
INTRODUCTION
Synapses are highly specialized structures with tightly apposed pre-and postsynaptic elements (Haucke et al., 2011) . While the basic building blocks of synapses within a cell may be similar, synaptic contacts are not invariant, and synaptic efficacy of individual release sites differs (Marrus et al., 2004; Peled and Isacoff, 2011; Pelkey et al., 2006; Schmid et al., 2008) . This heterogeneity suggests that presynaptic release site function may be locally regulated (Nicoll and Schmitz, 2005; Pelkey and McBain, 2007) . Thus, characterization of mechanisms that control the function of individual active zones will yield insight into the regulation of synaptic plasticity in health and disease.
Synaptic vesicles fuse at active zones, specialized presynaptic structures directly aligned to the postsynaptic receptor field (Petersen et al., 1997) . In Drosophila, active zones harbor electron-dense T bars, and Bruchpilot (BRP), a large cytoskeletal-like protein that is the ortholog of ELKS in mammals, is an integral part of these structures (Hida and Ohtsuka, 2010; Kittel et al., 2006) . BRP self-assembles in macromolecular entities where individual BRP strands join at their N-terminal ends near the plasma membrane while sending their C-terminal ends into the cytoplasm like a parasol (Fouquet et al., 2009; Jiao et al., 2010) . Similar to presynaptic specializations in other species, BRP is thought to capture synaptic vesicles using its C-terminal extensions, concentrating synaptic vesicles at active zones and facilitating synaptic transmission (Hallermann et al., 2010b; Zhai and Bellen, 2004) . Although the abundance of BRP at individual active zones correlates with the release efficiency (Graf et al., 2009; Marrus et al., 2004; Schmid et al., 2008) , little is known about the molecular mechanisms that regulate the function of presynaptic release sites. Here, we identify Elongator protein 3 (ELP3), a member of the elongator complex as a regulator of T bar function and morphology.
ELP3 was originally identified in yeast as a member of the nuclear elongator complex (Otero et al., 1999) . ELP3 harbors a Gcn5-related acetyltransferase (GNAT) domain and acetylates lysines in histone H3 (Han et al., 2008; Winkler et al., 2002) to modify DNA chromatin structure (Walia et al., 1998) . The ELP3 ortholog in plants is largely nuclear, however, in yeast and several other species, the protein also localizes to the cytoplasm where it is thought to take part in tRNA modification and acetylation of tubulin; however, the mechanistic details are elusive (Creppe et al., 2009; Solinger et al., 2010; Versé es et al., 2010) . Interestingly, ELP3 polymorphisms have been associated with decreased risk for amyotrophic lateral sclerosis (Simpson et al., 2009) , and mutations in ELP1 cause familial dysautonomia (Cheishvili et al., 2011; Slaugenhaupt and Gusella, 2002) .
To understand ELP3 function, we have investigated the neuronal role for ELP3 in vitro and in vivo. We show that presynaptic ELP3 loss of function results in altered morphology and function of T bars at fruit fly neuromuscular junctions (NMJs), and this occurs in the absence of defects in tubulin acetylation. We find that T bars in elp3 mutants change their structure in favor of forming more elaborate cytoplasmic extensions, that more synaptic vesicles are tethered to these T bars, and that neurotransmitter release becomes more efficient, including a larger readily releasable vesicle pool (RRP). Our data indicate that ELP3 is necessary and sufficient for BRP acetylation in vitro and in vivo, and we propose a model where, similar to acetylation of histones, acetylation of BRP regulates the cytoplasmic extensions of T bars, thereby controlling the capture of synaptic vesicles at active zones and neurotransmitter release efficiency.
RESULTS

Elp3 Is an Essential Gene
We previously isolated two EMS alleles of elp3 (elp3 1 and elp3 2 )
that harbor missense mutations in the acetyltransferase domain (Simpson et al., 2009 ) and now created independent null alleles 
ELP3 Localizes to Synapses
(A and B) elp3 locus, elp3 alleles (green) (A), and genomic elp3 constructs that express GFP N-and C-tagged ELP3 (B). elp3 D3 and elp3 D4 deletion mutants lack the SAM and GNAT domains, and elp3 D5 removes the start codon.
(C) Rescue of lethality of different elp3 mutants using one copy of GFP-elp3 + or elp3 + -GFP or using neuronal (nSyb-GAL4) or ubiquitous (Act-GAL4) expression of help3. Lethality scored on regular food while assessing if adult males and females emerged. Expression of help3 using BG57-GAL4 (muscular expression) did not rescue lethality (not shown combinations of the EMS alleles and the P element excision alleles die as early pupae, suggesting that all elp3 alleles we isolated are severe hypomorphic or null alleles (Walker et al., 2011) . To determine if the lethality and phenotypes of the elp3 alleles are solely due to loss of ELP3 function, we created transgenic flies that harbor genomic elp3 rescue constructs ( Figure 1B) (Venken et al., 2006) . The constructs allow expression of a C-or N-terminally GFP-tagged ELP3 under native control (Venken et al., 2008) . The presence of elp3 + -GFP or GFP-elp3 + in several heteroallelic combinations restores viability ( Figure 1C ; data not shown) and the cellular phenotypes in elp3 mutants (see below), indicating that only ELP3 function is affected in the mutants tested.
ELP3 Localizes to the Cytoplasm in Neurons and Enriches at Synapses
To determine the subcellular localization of Drosophila ELP3, we labeled elp3 + -GFP and GFP-elp3 + with several markers and assessed GFP distribution. While control animals not expressing GFP do not show labeling ( Figure 1F ; data not shown), in several cell types of third-instar larvae, including salivary gland cells and fat body cells, ELP3-GFP as well as GFP-ELP3 label the nucleus and/or the cytoplasm (Figures 1D and 1E ; data not shown). In contrast, in neurons of the ventral nerve cord (VNC) in third-instar larvae, we observe abundant ELP3 that concentrates in the cytoplasm, and we do not observe much nuclear labeling overlapping with Toto-3, a DNA marker. Furthermore, our data indicate that ELP3 concentrates in the synaptic-rich areas of the VNC and overlaps with the synaptic markers anti-Discs Large (DLG) and anti-Dynamin (DYN; Figures 1G-1J ; data not shown). Similarly, also in mouse motor neurons in culture, we observe abundant cytoplasmic ELP3 localization, indicating that this feature is evolutionary conserved (data not shown). In Drosophila larvae, ELP3-GFP is also present at the presynaptic side of NMJ boutons, double labeled with anti-DLG or with anti-DYN ( Figures  1K and 1L ). Thus, our data suggest a cytoplasmic role for ELP3 in motor neurons. To test whether ELP3 plays an important role in the nervous system, we generated transgenic animals that harbor a UAShuman ELP3 construct. Driving expression of hELP3 ubiquitously using Act-Gal4 rescues lethality associated with elp3 loss of function (elp3 1 /elp3 2 ; elp3 D3 /elp3 D4 ), and these flies show normal electroretinogram recordings (data not shown) (Simpson et al., 2009) , indicating that the construct is functional ( Figure 1C ). Driving hELP3 specifically in the nervous system using nsyb-Gal4 also rescues lethality of elp3 heteroallelic combinations ( Figure 1C , and see also below). In contrast, muscular hELP3 expression using BG57-Gal4 does not restore viability (data not shown). These data indicate an important role for ELP3 in the nervous system and presynaptically at the NMJ and also suggest that the function of ELP3 is evolutionary conserved.
Tubulin Acetylation Is Normal in elp3 Null Mutant Larvae ELP3 harbors an acetyltransferase domain, and recent evidence suggests that this function is important to mediate tubulin acetylation (Creppe et al., 2009; Solinger et al., 2010) . To test if ELP3 plays a role in neuronal tubulin acetylation in vivo, we labeled acetylated tubulin with specific antibodies in controls and elp3 null mutant Drosophila larvae. As a control we overexpressed HDAC6 (nsyb-GAL4), previously shown to act as a tubulin deacetylase (Hubbert et al., 2002) . While neuronal HDAC6 overexpression results in reduced acetylated tubulin labeling in motor neurons (Figures 2A, 2B , and 2E), loss of ELP3 function does not result in a difference in labeling intensity (Figures 2C-2E ; see Figures S1A-S1C available online). Similarly, western blot of acetylated tubulin also does not show a difference between elp3 null mutants and controls ( Figure 2F ). Furthermore, kinesin-driven axonal transport of synaptic vesicles, thought to be regulated by microtubule acetylation, is also not affected in elp3 mutants ( Figures S1D-S1F ), indicating that acetylation of microtubules in Drosophila larvae that lack elp3 is not affected. To test if ELP3 is involved in tubulin acetylation in vertebrates, we performed western blots using extracts of zebrafish embryos Figure S1 .
(30 hr post-fertilization [hpf]) treated with elp3 morpholinos or treated with control morpholinos ( Figure 2G ). As we reported before, elp3 morpholino treatment results in reduced motor axon length at 30 hpf (Simpson et al., 2009 ) ( Figure 2H ). However, elp3 knockdown does not show reduced levels of acetylated tubulin ( Figure 2G ). Consistently, treatment of fish with tubastatin, a specific inhibitor of HDAC6-mediated tubulin deacetylation, results in the expected increase in acetylated tubulin levels, but elp3 morpholino treatment does not counteract this effect ( Figure 2G ). Furthermore, tubastatin treatment fails to rescue elp3 morpholino-induced reduction in motor neuron axon length ( Figure 2H ), indicating that motor axon extension phenotypes upon elp3 morpholino treatment are not caused by decreased tubulin acetylation. Finally, we also assessed a role for ELP3 in the acetylation of microtubules in N2a, HEK, and NCS34 neuroblastoma cells as well as in mouse cortical neurons or motor neurons using elp3-siRNA or elp3-shRNA but did not observe a decrease in the acetylation status of microtubules ( Figure 2I ; Figures S1G-S1P). Thus, using different species and cell types, our data indicate that ELP3 is not a major acetyltransferase for tubulin, and suggest that ELP3 exerts neuronal functions without affecting tubulin acetylation.
BRP Spots Are Enlarged at elp3 Mutant NMJs
Given the cytoplasmic and synaptic localization of ELP3 in neurons, we assessed the abundance and localization of various markers at the Drosophila third-instar larval NMJ. We labeled control and elp3 mutant synapses with the periactive zone marker anti-FasiclinII (FASII), the synaptic vesicle markers antiCysteine string protein (CSP), anti-synaptobrevin (nSYB), and anti-vesicular glutamate transporter (vGLUT), with the endocytic marker anti-DYN and with the active zone markers anti-BRP
NC82
, anti-Liprin-a (LIP), and Cacophony-GFP (CAC). While most of the markers tested do not display a quantitative difference in labeling intensity or localization in elp3 mutants compared to controls, BRP NC82 immunoreactivity is markedly increased 3G; , and this defect is specific to loss of elp3, as adding a wild-type copy of elp3 completely rescues the defect ( Figures 3D, 3E , and 3G; data not shown). BRP NC82 recognizes BRP, an integral member of the electron-dense T bar within the active zone where synaptic vesicles fuse with the membrane ( Figure 3H ). However, given that other active zone markers including LIP and CAC do not show differences in labeling ( Figures 3B, 3C , and 3G), our data indicate specific synaptic defects in elp3 mutants, including increased BRP NC82 immunoreactivity at NMJ boutons.
BRP forms macromolecular assemblies that are involved in shaping the T bar (Fouquet et al., 2009) . Several ''BRP strands'' join at their N-terminal ends and contact Cacophony calcium channels near the presynaptic membrane (Kittel et al., 2006) , while BRP C-terminal ends extend into the cytoplasm (Figure 3H) . BRP NC82 antibodies label the BRP C-terminal portion, while anti-BRP N antibodies label the N-terminal end of the protein (Fouquet et al., 2009) . To further quantify the defect in BRP NC82 labeling, we measured dot number in controls and elp3 mutants. As shown in Figure 3J , we do not observe an increase in the number of BRP NC82 dots per boutonic area in elp3 mutants, and similarly, we also do not find a difference in the densities of dots per bouton of other active zone markers including LIP and CAC in elp3 mutants and controls ( Figures  3B, 3C , 3L, and 3M), indicating that elp3 mutations do not affect the number of active zones per synaptic area. Furthermore, compared to controls, we also do not observe altered calcium influx measured using GCaMP3 (Tian et al., 2009) did not find a difference, again indicating that ELP3 does not affect the number of active zones per bouton area ( Figure 3K ). Next, we also quantified BRP N dot size, but in contrast to BRP NC82 labeling, BRP dot size revealed by BRP N is very similar at elp3 mutant boutons and controls ( Figure 3O ), suggesting that T bar assembly per se (the number of BRP molecules) is not affected in elp3 mutants. We further assessed if in elp3 mutants supernumerous ''BRP strands'' join ( Figure 3H ), by also performing western blots of elp3 mutant and control brains probed with different BRP antibodies but found very similar BRP levels ( Figure 3I ; data not shown). Thus, the data indicate normal assembly of BRP strands at active zones and are consistent with morphological alterations at the C-terminal of BRP resulting in a more accessible BRP NC82 epitope in elp3 mutants.
Active Zones Are Malformed in elp3 Mutants
To directly assess active zone morphology in elp3 mutant and controls, we performed transmission electron microscopy (TEM). Quantification of several synaptic features, including synaptic vesicle number, synaptic vesicle size, mitochondrial number, and T bar number, does not reveal major differences between mutants and controls (Figures 4A-4C; Figure S3 ), indicating that elp3 mutations do not result in widespread synaptic defects or affect synaptic organelle transport. The most prominent feature in elp3 mutant boutons is the occurrence of sizable T bars with large protrusions that extend into the cytoplasm ( Figures 4D-4G , arrows). Quantification of T bar top lengths (platforms) in controls indicates that they never exceed 300 nm, while in elp3 mutants we observe more than 20% of the T bars with a platform that is larger than 300 nm and up to 400 nm in length (Figures 4D-4G, arrowheads; Figure 4H ). Thus, TEM indicates an increase in T bar size in elp3 mutants, and these data are consistent with the extensive ''tentacles'' extending into the cytoplasm in elp3 mutants that we observe in electron tomograms of elp3 mutant boutons ( Figures 4I-4O , arrows). In line with these data, we measure a concomitant increase in the number of synaptic vesicles that are in direct contact with the T bar ( Figure 4P) . Hence, the elaboration of the dense projections of the T bar in elp3 mutants results in an increased number of T bar-tethered vesicles.
Loss of elp3 Results in Larger Excitatory Junctional Currents and Miniature Excitatory Junctional Currents
To determine functional consequences associated with the loss of elp3 at the NMJ, we measured synaptic transmission using two electrode voltage clamp. The average excitatory junctional current (EJC) amplitude in 0.45 mM calcium is significantly increased in elp3 mutants ( Figures 5A and 5B ), and also current clamp recordings indicate increased excitatory junctional potential amplitudes in elp3 mutants compared to controls ( Figure S4 ).
To determine quantal content, we measured spontaneous vesicle fusion (mEJC) and quantified the quantal amplitude. As shown in Figures 5C-5F , mEJC amplitudes are significantly increased in elp3 mutants compared to controls, while the mEJC frequency trends toward an increase, but this is not statistically significant. The quantal content (in 0.45 mM calcium) also trends toward an increase but is not significantly different in controls and mutants (EJC/mEJC; controls, 45.3 ± 3.5 quanta; elp3 D3/D4 , 54.6 ± 6.7 quanta). Increased mEJC amplitude can be caused by larger synaptic vesicles that harbor more neurotransmitter or by a more elaborate postsynaptic glutamate receptor field. Given that synaptic vesicle size distribution in elp3 mutants is not different from controls, we labeled elp3 mutant NMJs with anti-GluRIIA 8B4D2 antibodies and with antiGluRIII/IIC antibodies that each recognize different glutamate receptor subunits (DiAntonio et al., 1999; Marrus et al., 2004 to controls, and this defect is rescued by a genomic fragment that harbors wild-type elp3 ( Figures 5I-5M ). These data are consistent with the increased mEJC amplitude in elp3 mutants to be caused by exuberant GluRIIA clustering.
Presynaptic Loss of elp3 Results in a Larger RRP
The number of T bar-tethered synaptic vesicles in elp3 is increased, and we tested whether a larger pool of synaptic vesicles is immediately ready for fusion in the mutants. First, we used fluctuation analysis to estimate the number of release-ready vesicles in controls and elp3 mutants. Given that EJC amplitudes in elp3 mutants and controls saturate at high calcium (Figure S5A) , we performed this analysis in the presence of a rapidly dissociating competitive receptor antagonist g-D-glutamylglycine (g-DGG) that has been used at the Drosophila larval NMJ before (Pawlu et al., 2004) . As shown in Figure S5A , EJC amplitudes recorded in 5 mM external calcium are reduced by 38% when incubated in 10 mM gDGG, and also mEJC amplitudes (recorded in 0.5 mM Ca 2+ ) are smaller both in controls (without gDGG 1.08 ± 0.05 nA; with gDGG 0.68 ± 0.05 nA; Figure S5B ) as well as in elp3 mutants (without gDGG 1.29 ± 0.07 nA; with gDGG 0.97 ± 0.03 nA; not shown). While in other systems application of gDGG results in a stronger inhibition of the postsynaptic response (Foster and Regehr, 2004) , our data are in line with previous results at the Drosophila NMJ (Pawlu et al., 2004) and indicate that gDGG at least in part prevents postsynaptic receptor saturation in high calcium concentrations. Recordings in the presence of the drug will thus allow us to assess neurotransmitter release while partly suppressing glutamate receptor saturation in controls and mutants.
We then recorded EJC amplitudes in gDGG and different calcium concentrations and extracted quantal parameters from parabolic fits from EJC variance versus EJC mean amplitude plots ( Figures S5C and S5D ) (Foster and Regehr, 2004) . Our data indicate a larger release-ready pool in elp3 mutants compared to controls (controls, 512.7 ± 35.1 quanta; elp3, 592.2 ± 41.3 quanta; p < 0.05). Also, we find a similar release probability (Pr) in controls and mutants in low calcium concentrations (Ca 2+ ): (0.3 mM) control 0.08 ± 0.001 and elp3 0.13 ± 0.01; (0.4 mM) control 0.20 ± 0.01 and elp3 0.17 ± 0.01; and (0.6 mM) control 0.27 ± 0.02 and elp3 0.24 ± 0.03. Similarly, in 3 mM calcium our analyses indicate a similar Pr (control, 0.98 ± 0.02; elp3, 0.96 ± 0.02), but under these conditions, postsynaptic receptor desaturation by gDGG may be incomplete ( Figure S5A ), confounding our estimations of the release-ready pool and Pr in the mutants. Nonetheless, in high calcium, Pr is invariably high, and differences in Pr, if any, between elp3 mutants and controls remain small.
To independently evaluate presynaptic release properties, we also measured transmission during a short train of highfrequency stimulation (500 ms, 100 Hz) in 5 mM external calcium, ensuring a high Pr ( Figure 6A ). This protocol results in the release of neurotransmitters from vesicles that are ready for fusion during the first stimulations and, subsequently, reveals the rate at which new vesicles are captured and prepared for release (30th-50th stimulation) (Hallermann et al., 2010a) . While the rate at which vesicles are refilled into the releasable pool during this stimulation paradigm is similar in elp3 mutants and controls (p > 0.05), back extrapolation from linear fits of the cumulative quantal content between the 30th and 50th stimulation reveals a larger pool of quanta that readily fuses in elp3 mutants compared to controls (control, 706.1 ± 36.9 quanta; elp3, 907.5 ± 52.2 quanta; p < 0.05). This effect is likely not caused by a postsynaptic change in receptor sensitivity as mEJC amplitude distribution in controls and in elp3 mutants before versus immediately following stimulation is similar ( Figures S5E and S5F) . Finally, we also recorded EJCs during a 500 ms 100 Hz train in the presence of gDGG, allowing us to perform recordings where the Pr is high, but postsynaptic receptor saturating is partly inhibited (Figures S5A-S5C ). As shown in Figure 6B , recordings in gDGG yield very similar results for the sizes of the RRP compared to recordings in the absence of the drug (control, 700.8 ± 27.5 quanta; elp3, 909.1 ± 40.7 quanta; p < 0.05). While gDGG may not completely block receptor saturation in high calcium, the data suggest that changes in postsynaptic receptor saturation are not the major cause of the larger number of detected quanta in elp3 mutants.
To determine the relative contribution of pre-or postsynaptic loss of elp3 to the defect we observe during high-frequency stimulation, we conducted rescue experiments. We expressed wild-type ELP3 (hELP3) using nsyb-Gal4 only in neurons (presynaptically at the NMJ) or using BG57-Gal4 only in muscles (postsynaptically at the NMJ) in elp3 null mutants. While neuronal expression of ELP3 rescues the increased BRP NC82 immunoreactivity ( Figures 6C, 6D Figures 6I-6L) . Thus, ELP3 is cell autonomously required in neurons to regulate BRP morphology and in muscles to restrict GluRIIA abundance.
Having established conditions where the postsynaptic GluRIIA defect is rescued and the presynaptic defect at the level of BRP is not, we evaluated the number of readily released quanta during a 500 ms 100 Hz stimulation train by back extrapolation. We find that expression of ELP3 in the nervous system of elp3 null mutants rescues the increased release seen in elp3 mutants (nsyb-Gal4/+, 688.1 ± 43.3; elp3 nsyb-Gal4, 620.2 ± 32.6; p > 0.05) (Figures 6A and 6M) . Conversely, when we assess the number of readily released quanta in elp3 mutants that express ELP3 in muscles, the pool size is still large (BG57/+, 716.3 ± 44.7; elp3 BG57, 961.3 ± 18.7; p < 0.05) (Figures 6A and 6N). Thus, the data indicate that the larger pool of quanta released under these conditions in elp3 mutants stems from a presynaptic defect.
To independently test for a presynaptic defect in vesicle release in elp3 mutants, we expressed synaptopHluorin (SpH). SpH is a synaptic vesicle-associated pH sensor. At low vesicular pH, SpH GFP is quenched but increases in fluorescence upon vesicle fusion (Miesenbö ck et al., 1998) . We monitored SpH fluorescence during a 500 ms 100 Hz stimulation paradigm, and while the initial baseline fluorescence (Fo) in controls and elp3 mutants is similar (data not shown), GFP fluorescence increases to a much higher level in elp3 mutants compared to controls (Figure 6O) . The data indicate that significantly more synaptic vesicles in elp3 mutants fuse during such a bout of stimulation. We do not believe that the increased fluorescence we observe is the result of defects in endocytosis in elp3 mutants, as our analyses have not revealed endocytic defects in the mutants (data not shown), and in addition, a potential defect in endocytosis would not be expected to significantly contribute to the increase in fluorescence within this short time period.
ELP3 Is Necessary and Sufficient for BRP Acetylation
Given that elp3 mutants show morphological defects at the level of their T bars, we tested whether BRP is a substrate for ELP3-dependent acetylation. First, we expressed Drosophila HIS-ELP3 in E. coli, purified, and refolded the protein (Figures S6A  and S6B ). Acetyltransferases are prone to autoacetylation (Choudhary et al., 2009) . We therefore incubated ELP3 with 20 mM Acetyl-CoA for various time periods. Western blots probed with antibodies against acetylated lysine (Ac-K) indicate time-dependent ELP3 autoacetylation ( Figure 7A ). Next, we tested whether our ELP3 protein can acetylate purified histone H3, a well-established target, and tubulin. Our data indicate both concentration-and time-dependent acetylation of histone UAS-help3; BG57-GAL4/+ (elp3 mutant with muscular ELP3 expression F and F 0 ) with anti-
GluRIIA intensity relative to anti-HRP, and data are normalized to control (%). n, number of NMJs from at least four animals (indicated in the bars). Neuron ELP3 Acetylates BRP H3 ( Figure 7B ), but we did not observe ELP3-dependent acetylation of tubulin in wild-type fly lysate, or in lysate prepared from elp3 null mutant animals (Figures 7C and 7E ; data not shown). Thus, although our ELP3 fraction is active, it does not support acetylation of tubulin in vitro. Finally, we tested acetylation of BRP in vitro. We immunoprecipitated BRP from fly heads (see also Figure 8H ), incubated these BRP-enriched fractions with Acetyl-CoA and ELP3, and probed western blots with Ac-K ( Figure 7D ). As shown in Figures 7D and 7F , we find obvious time-dependent acetylation of BRP. These data indicate that ELP3 is sufficient for the acetylation of the active zone-associated protein BRP. To determine if ELP3 acetylates BRP in vivo, we labeled NMJs with Ac-K. Ac-K labels histones in nuclei (data not shown), microtubules in axons that we marked using the monoclonal antibody Futsch 22C10 ( Figures 8A and 8B) , as well as several features in synaptic boutons ( Figures 8A and 8C) . Furthermore, overexpression of HDAC6 shows a marked reduction in Ac-K that decorates microtubules labeled by Futsch 22C10 , indicating that the antibodies are specific ( Figure 8E ). Interestingly, antiacetylated lysine labeling that overlaps with BRP NC82 labeling is much reduced in elp3 mutants compared to controls ( Figures  8C, 8D , 8F, and 8G). The reduction in labeling is specific to active zones because Ac-K labeling overlapping with Futsch 22C10 is not significantly different in elp3 mutants compared to controls ( Figures 8A, 8B , and 8E). The data suggest that less acetylated lysines are present at active zones in elp3 mutants. Next, we immunoprecipitated BRP from control and elp3 RNAi-expressing pharate adult brains and probed western blots Western blots were probed with Ac-K and reprobed with BRP D2 .
(E and F) Quantification of ELP3-dependent acetylation of tubulin and of BRP normalized to total tubulin or total BRP levels relative to initial acetylation levels (time point ''0''). Number of independent repeats is indicated in the bars.
with Ac-K. BRP immunoprecipitations (IPs) from control animals show an acetylated lysine band that migrates at the same height of BRP, detected with antibodies against the middle domain of BRP, BRP D2 ( Figures 8H and 7D ). This band is largely absent in western blots of IPs from pharate adult brains that express RNAi to brp, indicating that the band is specific to BRP and suggesting that at least some BRP is acetylated under basal conditions. Interestingly, in BRP IPs from animals that express RNAi to elp3, we are able to clearly detect BRP, but the acetylated lysine band at the height of BRP is largely absent ( Figure 8H ). These data corroborate the labeling of acetylated lysines at boutons and suggest that ELP3 is necessary to maintain the acetylation status of the active zone-associated protein BRP.
DISCUSSION
In this work we provide evidence that ELP3 acetylates the active zone-associated cytoskeletal-like protein BRP that is increasingly implicated in neuronal diseases (Choi et al., 2010; Zweier et al., 2009 ). ELP3-mediated BRP acetylation regulates dense body structure, akin to the modification of chromatin structure in the nucleus, and this function is independent of an effect of ELP3 on tubulin acetylation. We suggest that decreased BRP acetylation in elp3 mutants results in expanded cytoplasmic specializations that capture synaptic vesicles, and our work points to a model where individual release site morphology and function may be controlled by BRP acetylation.
Tubulin Acetylation in the Absence of ELP3 Recent work suggests that besides a role in acetylating histones, ELP3 also acetylates tubulin (Creppe et al., 2009; Solinger et al., 2010) ; however, several of our observations using different species and cell types indicate that microtubules can be acetylated by a mechanism that does not involve ELP3. Similar to our findings, in human neuroblastoma cells or in mouse embryonic fibroblasts, ELP1 knockdown results in a profound reduction of ELP3 expression, but also this condition did not affect the levels of acetylated tubulin (Cheishvili et al., 2011) . Although in vitro our ELP3 fraction was not able to increase tubulin acetylation, when the protein is overexpressed in N2a cells or in Drosophila motor neurons, we find a mild increase in acetylation of tubulin (data not shown), but our work shows that this activity is limited outside of overexpression conditions. It is interesting that an alternative GNAT domain protein, MEC-17, was shown to acetylate tubulin in different systems, including nematodes, zebrafish, and ciliates (Akella et al., 2010) ; in addition, an acetyltransferase complex, ARD1-NAT1, that can acetylate tubulin in vitro has been found associated with tubulin in developing dendrites of cultured hippocampal neurons and was shown to regulate dendritic outgrowth in vitro (Ohkawa et al., 2008) . Thus, alternative tubulin acetyltransferases that regulate neuronal morphology have been identified.
ELP3 Is a BRP Acetyltransferase and Controls Active Zone Morphology
In a search of alternative cytoplasmic ELP3 targets, we identified BRP, a large cytoskeletal-like protein that decorates the active zone where synaptic vesicles fuse with the membrane. We provide several lines of evidence that ELP3 acts to acetylate BRP at the Drosophila NMJ. First, ELP3 is present at NMJ boutons, localizing the enzyme in close proximity to BRP. Second, acetylated lysine levels that overlap with BRP NC82 labeling at the NMJ are reduced in elp3 mutants. Similarly, BRP-associated acetylated lysine levels detected by western blotting are reduced in elp3 mutants. Third, immunoprecipitated BRP is efficiently acetylated by purified ELP3 in vitro. Without excluding other substrates, our data indicate that ELP3 is necessary and sufficient to acetylate BRP. BRP is indeed an excellent candidate to undergo this modification as it contains numerous coiledcoil motifs that were recently shown to be ideal acetylation substrates (Choudhary et al., 2009) . Individual BRP strands organize into parasol-like structures, with their N termini facing the plasma membrane, contacting calcium channels, and their C termini extending into the cytoplasm capturing synaptic vesicles (Fouquet et al., 2009; Hallermann et al., 2010b; Jiao et al., 2010) . While mutations that affect BRP transport to synapses or assembly of T bars at active zones exist, our data indicate that these processes are not affected in elp3 mutants. Unlike SRPK79D mutants (Johnson et al., 2009; Nieratschker et al., 2009) , BRP NC82 does not accumulate in elp3 mutant motor neurons (data not shown), suggesting normal axonal transport. In addition, in contrast to rab3 mutants (Graf et al., 2009 ), the number of T bars per synaptic area is not different in controls and elp3 mutants.
Our analyses also identified a postsynaptic role for elp3 in regulating glutamate receptor subunit IIA abundance in muscles at NMJs and, thus, mEJC amplitude; however, unlike ELP3's neuronal function, we show that this role of ELP3 is not critical for viability, as muscular expression of the protein does not rescue elp3-associated lethality. Nonetheless, by regulating postsynaptic receptor field size, ELP3 may also modulate neuronal communication. We present evidence that this defect is regulated in muscle cells independently of the presynaptic role of ELP3.
Using different independent methodologies, we provide evidence that ELP3 regulates presynaptic neurotransmitter release efficiency. We show that during a short high-frequency stimulation train, elp3 mutants show a stronger increase in SpH fluorescence than controls. Furthermore, mutants release more quanta than controls during a short 100 Hz stimulation train, and this is also true in mutant animals that express hELP3 in muscles and, thus, do not display increased GluRIIA levels. While these data are consistent with a larger pool of readily releasable vesicles in the mutants, a larger Pr in elp3 mutants may also contribute to increased release. Given that gDGG only partially prevents postsynaptic receptor saturation 
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ELP3 Acetylates BRP at the NMJ, our estimates of Pr in high calcium based on fluctuation analysis are less accurate. However, in 5 mM calcium the Pr is invariably high, limiting the difference in Pr between controls and mutants. In addition, an increased Pr but not a larger RRP in elp3 mutants would alter the time course by which neurotransmitters are released during the 500 ms 100 Hz stimulation paradigm, but the total number of released quanta would not be different between elp3 mutants and controls, particularly in mutants where the postsynaptic defects are rescued, and differences in receptor abundance are eliminated. Thus, while not excluding an effect of ELP3 on the Pr in high calcium, our data are most consistent with an increased RRP in elp3 mutants.
Our work suggests a model where acetylation of BRP reorganizes the cytoplasmic tentacles such that deacetylation leads to more extensive spreading of the strands, possibly by altering electrostatic interactions, similar to the regulation of chromatin structure by histone acetylation (Shogren-Knaak et al., 2006) . At active zones, we speculate that this function regulates vesicle capturing by the C-terminal end of BRP (Hallermann et al., 2010b) , and transport of vesicles at dense bodies. We present evidence that the defect in elp3 mutants results in a larger pool of synaptic vesicles that is ready for immediate release, potentially in part by improved vesicle tethering at T bars. Although the mechanisms that regulate local ELP3 activity levels at the synapse (but also those that regulate ELP3 activity in the nucleus) remain elusive, it will be interesting to identify signaling pathways that activate ELP3 enzymatic function. The local regulation of ELP3 may enable single active zones to control neurotransmitter release and may have important implications for synaptic transmission regulation in a number of neurological diseases, including ALS and familial dysautonomia (Simpson et al., 2009; Slaugenhaupt and Gusella, 2002) .
EXPERIMENTAL PROCEDURES Animals and Cells
All Drosophila lines were kept on cornmeal and molasses medium. For experiments L3 larvae were grown on black currant juice agar plates with fresh yeast paste. GAL4 > UAS-expressing larvae and controls were raised at 28 C (rescue and HDAC6) or at 25 C (CAC-GFP, GCaMP3, SpH, and RNAi . Adult zebrafish (AB) and embryos were maintained and staged as described (Westerfield, 2003) . The elp3 ATG-morpholino is from Gene Tools, LLC (Corvallis, OR, USA):
A total of 2 mM tubastatin A or DMSO treatment was started at 6 hpf. Axonal defects were evaluated at 30 hpf (Lemmens et al., 2007) . N2a, HEK293T, and NSC34 cells were grown under standard conditions, and cortical neurons, motor neurons, and glial feeder layer cells were prepared as described (Vandenberghe et al., 1998) .
Constructs UAS-help3 was created by cloning the human elp3 cDNA (OriGene) into the EcoRI site of pUAST-attB. Genomic GFP-elp3 + and elp3 + -GFP constructs were generated using recombineering in attB-P(acman)-Ap R (Venken et al., 2006 (Venken et al., , 2008 using BAC RP98-28K16. These constructs were inserted in VK31 (62E1) and VK01 (59D3) sites using phiC31-mediated integration (GenetiVision, Houston). For protein expression, Drosophila elp3 cDNA (RE35395, BDGP) was cloned into a pDEST14 expression vector using Gateway technology (Invitrogen) and includes an N-terminal 6xHIS tag.
Biochemistry Drosophila, zebrafish, and cellular extracts for westerns were prepared using standard procedures and probed with the antibodies listed below.
IP of BRP from pupal or adult brain extracts was performed using BRP NC82 diluted 1:5 (Developmental Studies Hybridoma Bank, Iowa City, IA, USA) and G protein-coupled magnetic beads (BioLabs) using Drosophila head lysate (Supplemental Experimental Procedures), and IPed protein was either used for acetylation assays or for westerns. Drosophila ELP3 was expressed in E. coli Rosetta (DE3) pLysS cells (Promega). In vitro acetylation was performed by incubating purified ELP3 with substrate in acetylation buffer (50 mM Tris-HCl [pH 8.0], 0.1 mM EDTA, 1 mM DTT, 10 mM Na-butyrate, 10% glycerol) and 20 mM acetyl CoA (Sigma-Aldrich) at 25 C (Chen and Greene, 2005) . Substrates used were purified Histone H3 (Westburg) and beads with BRP or Drosophila head protein lysate (for acetylation of tubulin). Western blotting antibodies were: 1:500 anti-Acetylated lysine (Ac-K) (rabbit, AB80178; abCAM); 1:1,000 anti-BRP N and 1:1,000 anti-BRP D2 (Fouquet et al., 2009) ; 1:1,000 anti-neuronal synaptobrevin (nSYB
R29
) and 1:500 anti-Histone H3 (9715L; Cell Signaling); 1:10,000 anti-Acetylated a-Tubulin (6-11-B-1; Sigma-Aldrich); 1:1,000 anti-a-Tubulin (B5-12; SigmaAldrich); 1:5,000 anti-b-actin (A5441; Sigma-Aldrich); 1:1,000 anti-BRP NC82 (Developmental Studies Hybridoma Bank); 1:5,000 anti-GAPDH (4300; Ambion); and 1:1,000 HRP-coupled secondary antibodies (Jackson ImmunoResearch). Blots were developed with Western Lightning ECL (PerkinElmer).
Fluorescence Microscopy
Drosophila third-instar larvae were prepared as described (Uytterhoeven et al., 2011 (Zinsmaier et al., 1994) ; 1:1,000 anti-HRP (Jackson ImmunoResearch); 1:300 anti-BRP N and 1:1,000
anti-Liprin (Owald et al., 2010) ; 1:200 anti-DYN (Hudy1; Millipore); 1:500 antinSYB R29 and 1:200 anti-Syndapin (both gifts from H. Bellen, BCM); 1:500 anti-GLURIII (Marrus et al., 2004) ; 1:10,000 anti-vGLUT (Daniels et al., 2004) (both gifts from A. Di Antonio, Washington University); 1:200 anti-Acetylated Lysines (Ac-K) (ab80178; abCAM); 1:1,000 anti-Acetylated a-Tubulin (6-11-B-1; Sigma-Aldrich); 1:500 anti-GFP (rabbit IgG fraction; Invitrogen) to detect GFP-ELP3, ELP3-GFP, and Cac-GFP signals; and 1:1,000 secondary Alexa 488, 555, or 645-conjugated antibodies (Invitrogen). Toto3 (Invitrogen) was used to label DNA and was used at 1:500 in PBS prior to mounting samples. NMJs were imaged through 633 1.4 NA oil lens on a Zeiss 510 Meta confocal microscope, and mean fluorescence intensities of labeling per bouton and background were measured using ImageJ as described (Khuong et al., 2010; Uytterhoeven et al., 2011) . The number of BRP spots per area was counted following automated thresholding in ImageJ and calculated from measurements of R 6 type 1b boutons per NMJ on M6/7 in segments A2/3.
Electron Microscopy L3 larvae were dissected in HL-3 and prepared for TEM, and bouton profiles in 50 nm sections from M6/7 in segment A2 were visualized on a JEOL TEM100 (Uytterhoeven et al., 2011) . At least 17 images from 3 animals were analyzed. Serial-tilt EM was performed on 300 nm sections, and micrographs were recorded from À60 to 60 at 2 intervals. 3D reconstructions were generated in IMOD (Uytterhoeven et al., 2011) .
Electrophysiology
Recordings from L3 M6 in segment A2/3 were performed on an Axoclamp 900A amplifier, filtered at 1 kHz (400 Hz for minis), and stored in pClamp 10.3 in modified HL-3: 110 mM NaCl, 5 mM KCl, 10 mM NaHCO 3 , 5 mM HEPES, 30 mM sucrose, 5 mM trehalose, 10 mM MgCl 2 , CaCl 2 (as indicated) [pH 7.2], using a holding potential of À70 mV (Uytterhoeven et al., 2011) . Where indicated, 0.5 mM TTX (for mini recordings, not in Figures S6E and S6F ) or 10 mM g-DGG (Tocris Bioscience) was added (Pawlu et al., 2004) for 10 min prior to recordings. Fluctuation analysis was performed as described (Weyhersmü ller et al., 2011).
The RRP size from cumulative EJC plots was determined as described (Weyhersmü ller et al., 2011; Hallermann et al., 2010a) except that 50 stimuli were delivered at 100 Hz. EJC amplitudes were measured from peak to the baseline (lowest level) immediately before the onset of the EJC. Trend lines were calculated between the 30th and 50th stimulation point and back extrapolated to time zero.
Time-Lapse Imaging
GCaMP3 and SpH were expressed with nSyb-Gal4 in elp3 rev and elp3 mutants, and imaging was performed as described (Hendel et al., 2008; Uytterhoeven et al., 2011) .
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